Physician profile
Mindy E Wenger
NPI 1982784559
$4,105.63
in general payments reported to CMS, 2019-2025
32 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $363 · 2023: $730 · 2024: $1,455 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,538.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $874.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $459.14 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $415.25 | 2022-2025 | |
| Lilly USA, LLC | $290.84 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $249.33 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $246.52 | 2023-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $209.85 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.12 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $131.73 | 2023-2025 | |
| Lundbeck LLC | $103.12 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.60 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $91.87 | 2025 | Korlym |
| Exact Sciences Corporation | $77.04 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $74.31 | 2023-2025 | Trintellix |
| Amarin Pharma, INC. | $72.25 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $68.29 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $63.47 | 2022-2023 | |
| Esperion Therapeutics, INC. | $52.37 | 2022-2025 | Nexletol |
| Glaxosmithkline, LLC. | $51.62 | 2021-2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $48.35 | 2023-2024 | Voquezna |
| Astellas Pharma US INC | $46.19 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $43.71 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $39.70 | 2023-2024 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $35.62 | 2023-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.62 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $17.54 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.20 | 2024 | |
| Seqirus USA INC | $16.44 | 2025 | Flucelvax, Fluad |
| Smith+Nephew, INC. | $15.58 | 2024 | Collagenase Santyl |
| Acella Pharmaceuticals, LLC | $15.31 | 2024 | NP Thyroid 60 |
| Sanofi Pasteur INC. | $14.75 | 2023 | |
| Dexcom, INC. | $13.79 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Wenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.